| 25.47 0.7 (2.83%) | 08-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 32.05 | 1-year : | 35.33 |
| Resists | First : | 27.44 | Second : | 30.25 |
| Pivot price | 25.66  |
|||
| Supports | First : | 22.9 | Second : | 19.06 |
| MAs | MA(5) : | 24.42 |
MA(20) : | 26.25 |
| MA(100) : | 25.87 |
MA(250) : | 16.79 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 27.5 |
D(3) : | 19.7 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 34.38 | Low : | 6.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TNGX ] has closed above bottom band by 46.4%. Bollinger Bands are 28.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.98 - 27.08 | 27.08 - 27.16 |
| Low: | 24.01 - 24.12 | 24.12 - 24.22 |
| Close: | 25.29 - 25.45 | 25.45 - 25.6 |
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Wed, 26 Aug 2026
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Thu, 20 Aug 2026
Farallon Capital Management Adds to Tango Therapeutics (TNGX) St - GuruFocus
Wed, 19 Aug 2026
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift - simplywall.st
Sun, 16 Aug 2026
Tango Therapeutics: Promising Early Data, But A Long Road Ahead - Seeking Alpha
Fri, 14 Aug 2026
Woodline holds 4.0M Tango Therapeutics (TNGX) shares, a 2.5% stake - Stock Titan
Tue, 11 Aug 2026
Tango Therapeutics (Nasdaq: TNGX) posts higher loss while amassing $1B cash for oncology trials - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 169 (M) |
| Shares Float | 120 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 129 (%) |
| Shares Short | 44,610 (K) |
| Shares Short P.Month | 42,010 (K) |
| EPS | -0.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.72 |
| Profit Margin | -230 % |
| Operating Margin | -253.4 % |
| Return on Assets (ttm) | -13 % |
| Return on Equity (ttm) | -21.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.48 |
| Sales Per Share | 0.31 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -144 (M) |
| Levered Free Cash Flow | -72 (M) |
| PE Ratio | -30.33 |
| PEG Ratio | 0 |
| Price to Book value | 9.36 |
| Price to Sales | 79.8 |
| Price to Cash Flow | -29.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|